Percheron Therapeutics Limited (ATHJF)

0.0100 0.0000 (0.00%) At close: 02:18PM EDT

Percheron Therapeutics Limited

L30, Collins Place
35 Collins Street
Melbourne, VIC 3000
Australia
61 3 9827 8999
https://www.PercheronTx.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. James Garner B.Sc (Hons), B.Sc., M.A., M.A.I.C.D., M.B.A., MBA	CEO, MD & Director	6.38k	N/A	1973
Dr. Anthony Filippis	Chief Operating Officer	215.43k	N/A	N/A
Mr. Phillip Allen Hains BBus(Acc), C.A., M.B.A.	CFO & Joint Company Secretary	N/A	N/A	1959
Ms. Alicia Mellors	Joint Company Secretary	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase IIa clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023. The company was incorporated in 2000 and is based in Melbourne, Australia.

Corporate governance

Percheron Therapeutics Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.